BioLine RX Ltd
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the t… Read more
BioLine RX Ltd (BLRX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.108x
Based on the latest financial reports, BioLine RX Ltd (BLRX) has a cash flow conversion efficiency ratio of -0.108x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA-2.11 Million) by net assets (ILA19.53 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
BioLine RX Ltd - Cash Flow Conversion Efficiency Trend (2010–2024)
This chart illustrates how BioLine RX Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
BioLine RX Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BioLine RX Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Northview Residential REIT
TO:NRR-UN
|
0.039x |
|
FORD MOTOR (FMC1.SG)
STU:FMC1
|
0.124x |
|
The Social Chain AG
F:PU11
|
N/A |
|
ESCALADE
BE:ED9
|
0.062x |
|
MAJ DRILL GRP INTL
MU:3MJ
|
0.081x |
|
SKY PER JSAT HLDGS
BE:SKM
|
0.065x |
|
AB Effectenbeteiligungen AG
STU:JPH
|
N/A |
|
FIFTH ST FINANCE
BE:FFC
|
-0.040x |
Annual Cash Flow Conversion Efficiency for BioLine RX Ltd (2010–2024)
The table below shows the annual cash flow conversion efficiency of BioLine RX Ltd from 2010 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ILA13.46 Million | ILA-43.87 Million | -3.259x | -90.63% |
| 2023-12-31 | ILA13.22 Million | ILA-22.61 Million | -1.710x | -231.27% |
| 2022-12-31 | ILA50.84 Million | ILA-26.24 Million | -0.516x | -49.07% |
| 2021-12-31 | ILA68.09 Million | ILA-23.57 Million | -0.346x | +67.13% |
| 2020-12-31 | ILA22.03 Million | ILA-23.21 Million | -1.053x | -55.13% |
| 2019-12-31 | ILA33.38 Million | ILA-22.67 Million | -0.679x | -15.98% |
| 2018-12-31 | ILA41.32 Million | ILA-24.19 Million | -0.585x | -50.68% |
| 2017-12-31 | ILA52.88 Million | ILA-20.55 Million | -0.389x | +6.22% |
| 2016-12-31 | ILA35.03 Million | ILA-14.51 Million | -0.414x | -39.23% |
| 2015-12-31 | ILA47.61 Million | ILA-14.17 Million | -0.298x | +34.72% |
| 2014-12-31 | ILA31.77 Million | ILA-14.48 Million | -0.456x | +73.68% |
| 2013-12-31 | ILA11.68 Million | ILA-20.23 Million | -1.732x | -28.90% |
| 2012-12-31 | ILA14.97 Million | ILA-20.11 Million | -1.344x | -169.77% |
| 2011-12-31 | ILA22.53 Million | ILA-11.22 Million | -0.498x | -673.33% |
| 2010-12-31 | ILA131.96 Million | ILA11.46 Million | 0.087x | -- |